Research Topics
Species | SOFIA DIANA MERAJVERSummaryAffiliation: University of Michigan Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1Min Lin
Division of Hematology Oncology, Department of Internal Medicine, The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
Mol Cancer 4:21. 2005..RhoC GTPase is overexpressed in aggressive cancers that metastasize and is the predominant GTPase in PC. Like several GTPases, RhoC contains a putative cav-1 binding motif...- Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cellsYanhong Zhang
Department of Pathology, University of Michigan Medical Center, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
Breast Cancer Res 7:R1080-9. 2005..We hypothesized that inhibition of CCN6 might result in the loss of a growth regulatory function that protects mammary epithelial cells from the tumorigenic effects of growth factors, particularly IGF-1... - WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancerCelina G Kleer
Department of Pathology, University of Michigan, Ann Arbor, MI, USA
Breast Cancer Res 6:R110-5. 2004..We propose a model of this interaction as a starting point for further investigations... 
Multifaceted role of Rho proteins in angiogenesisSofia D Merajver
Breast and Ovarian Cancer Risk Evaluation Program, University of Michigan Comprehensive Cancer Center, 7217 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0948, USA
J Mammary Gland Biol Neoplasia 10:291-8. 2005..Concordant with their roles in multiple processes of cellular control, the Rho proteins have been shown to be involved in tumor growth, progression, metastasis, and now angiogenesis...- Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experienceS D Merajver
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109 0680, USA
J Clin Oncol 15:2873-81. 1997..To determine whether breast conservation and prolonged neoadjuvant chemotherapy have efficacy in locally advanced breast cancer (LABC), as measured by survival and rate of breast conservation... - Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivityMichelle L Wynn
Center for Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA
BMC Syst Biol 5:156. 2011..We hypothesize that targeted therapies such as kinase inhibitors can produce off-target effects as a consequence of retroactivity alone... - Breast cancer risk assessment: a guide for clinicians using the NCCN Breast Cancer Risk Reduction GuidelinesSofia D Merajver
Breast and Ovarian Cancer Risk Evaluation Clinic, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
J Natl Compr Canc Netw 1:297-301. 2003..This article summarizes these models and gives brief guidelines about which model may be preferable given a specific family history... - Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancerKenneth L van Golen
Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109 0948, USA
Clin Exp Metastasis 19:301-11. 2002..We found that activation of the MAPK pathway was responsible for motility, invasion and production of angiogenic factors. In contrast, growth under anchorage independent conditions was dependent on the PI3K pathway... - Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancerBasil Hassouneh
Department of Otolaryngology Head and Neck Surgery, University of Michigan, 1500 East Medical Centre Drive, 1904 Taubman Center, Ann Arbor, MI 48109, USA
Mol Cancer Ther 6:1039-45. 2007..Taken together, these results show that tetrathiomolybdate can act long-term as a suppressor of vascularity and inhibit the growth of metastasis in this model of HNSCC... - Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiencyGazala N Khan
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
Curr Pharm Des 13:3584-90. 2007..We use these strategies as paradigms of how to make progress in this difficult but important area of translational research... - Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascadeQuintin Pan
Department of Internal Medicine, Division of Hematology and Oncology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Mol Cancer Res 1:701-6. 2003..Taken together, these results strongly support that suppression of NFkappaB is the major mechanism used by TM to inhibit angiogenesis and metastasis... - Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesisQuintin Pan
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Cancer Res 62:4854-9. 2002..Our study suggests that a major mechanism of the antiangiogenic effect of copper deficiency induced by TM is suppression of NFkappaB, contributing to a global inhibition of NFkappaB-mediated transcription of proangiogenic factors... - RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neckCelina G Kleer
Department of Pathology, University of Michigan, Ann Arbor, 48109, USA
Clin Cancer Res 12:4485-90. 2006..This study evaluated the expression of RhoC in head and neck carcinoma and investigated the prognostic use of this marker on a large cohort of previously untreated patients with SCCHN... - Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1Wei Huang
Department of Pathology, University of Michigan Medical School, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0605, USA
Am J Pathol 172:893-904. 2008..Together, our results lead to a new hypothesis that Snail and ZEB1 are downstream of CCN6 and play a critical role in CCN6-mediated regulation of E-cadherin in breast cancer... - Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitorKenneth L van Golen
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA
Mol Cancer Ther 1:575-83. 2002..These data provide direct evidence that FTIs may find use in the clinic when directed against RhoC-overexpressing tumors and suggest appropriate biological markers to evaluate during FTI treatment... - WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancerCelina G Kleer
Department of Pathology, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48108, USA
Neoplasia 6:179-85. 2004.... - RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cellsMei Wu
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109-0948, USA
Breast Cancer Res Treat 84:3-12. 2004..We have further verified by quantitative RT-PCR that genes involved in cell proliferation, invasion/adhesion, and angiogenesis were modulated by RhoC. This work suggests strong candidates for the downstream oncogenic functions of RhoC... - Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancerLiWei Bao
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
Cancer Res 69:5829-34. 2009..02) retards the growth of UMSCC1 xenografts in nude mice. Our work indicates that the bifunctional HN1-PKCepsilon inhibitory peptide represents a promising novel therapeutic strategy for HNSCC... 
Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancersMei Wu
Department of Internal Medicine, Division of Hematology and Oncology and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan
Cancer 116:2768-82. 2010..The 2 closely related small GTPases, RHOC and RHOA, are involved in mammary gland carcinogenesis; however, their specific roles in determining cancer cell adhesion and invasion have not been elucidated...- Rho proteins and cell-matrix interactions in cancerMei Wu
Division of Hematology and Oncology and Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich 48109 0948, USA
Cells Tissues Organs 185:100-3. 2007..In this mini-review, we discuss the functions of the Rho proteins and their relationship with other signaling pathways in matrix remodeling and integrin signaling of highly motile and invasive cancer cells... - CCG-1423: a small-molecule inhibitor of RhoA transcriptional signalingCHRIS R EVELYN
Department of Pharmacology, University of Michigan Medical Center, 1301 MSRB III, Room 2220D, 1150 West Medical Center Drive, Ann Arbor, MI 48109 0632, USA
Mol Cancer Ther 6:2249-60. 2007..Thus, based on its profile, CCG-1423 is a promising lead compound for the development of novel pharmacologic tools to disrupt transcriptional responses of the Rho pathway in cancer... - Molecular determinants of the inflammatory breast cancer phenotypeNathan W Houchens
Department of Internal Medicine, University of Michigan, Health System, USA
Oncology (Williston Park) 22:1556-61; discussion 1561, 1565-8, 1576. 2008.... - Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapyMei Wu
Department of Internal Medicine, Division of Hematology and Oncology and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109-0948, USA
Breast Dis 22:25-34. 2005..In this review, we discuss the current advances in understanding the genetic determinants of IBC with emphasis on their present and potential applications to diagnosis, prognosis, and treatment... - Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patientsAn Chi Lo
Department of Epidemiology, University of Michigan School of Public Health, 109 Observatory Street, Ann Arbor, MI 48109, USA
Breast Cancer Res Treat 112:141-7. 2008..A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors... - WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancerCelina G Kleer
Department of Pathology, Univeristy of Michigan, Ann Arbor, MI, USA
Breast Cancer Res 6:R110-5. 2004..This provides further evidence that these two genes act in concert to give rise to the highly aggressive IBC phenotype. We propose a model of this interaction as a starting point for further investigations... - BRCA1 regulates human mammary stem/progenitor cell fateSuling Liu
Comprehensive Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
Proc Natl Acad Sci U S A 105:1680-5. 2008..Because BRCA1 also plays a role in DNA repair, our work suggests that loss of BRCA1 may result in the accumulation of genetically unstable breast stem cells, providing prime targets for further carcinogenic events... - Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinomaKenneth L van Golen
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0948, USA
Neoplasia 4:373-9. 2002..Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy... - WISP3 is a novel tumor suppressor gene of inflammatory breast cancerCelina G Kleer
Department of Pathology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0054, USA
Oncogene 21:3172-80. 2002..Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis... - Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in EgyptSubhojit Dey
Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, MI, 48109, USA
Breast Cancer Res Treat 120:149-60. 2010..ER-incidence rate was 2-3 times (IRR = 1.86, 95% CI = 2.38, 1.45) higher in urban areas than in rural areas. Our findings indicate that urban women may probably have a higher exposure to xenoestrogens... - Radiotherapy and antiangiogenic TM in lung cancerMohamed K Khan
Department of Radiation Oncology, The University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
Neoplasia 4:164-70. 2002..We also show that their therapeutic effects are additive, with no additional toxicity. We show that TM has no significant cytotoxicity in vitro against LLHM tumor cells, further supporting the antiangiogenic mechanism for its action... - Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapyQuintin Pan
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Health System, Ann Arbor, Michigan 48109, USA
Cancer Res 65:8366-71. 2005..Taken together, these results revealed that PKC epsilon plays a critical and causative role in promoting an aggressive metastatic breast cancer phenotype and as a target for anticancer therapy... - Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic abilityCelina G Kleer
Department of Pathology, Division of Hematology and Oncology, 2G332 University Hospital, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0054, USA
Am J Pathol 160:579-84. 2002..RhoC is specifically expressed in invasive breast carcinomas capable of metastasizing, and it may be clinically useful in patients with tumors smaller than 1 cm to guide treatment... - Pomegranate fruit extract impairs invasion and motility in human breast cancerGazala N Khan
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
Integr Cancer Ther 8:242-53. 2009..Because nuclear transcription factor-kB (NF-kB) is known to regulate cell survival, proliferation, tumorigenesis, and inflammation, it was postulated that PFEs may exert anticancer effects at least in part by modulating NF-kB activity... - Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomyLori J Pierce
Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive Room 4308, Ann Arbor, MI 48109, USA
Breast Cancer Res Treat 121:389-98. 2010..However, women undergoing BCT have an elevated risk of a second in-breast event that is significantly reduced in the presence of chemotherapy. Contralateral breast cancer events are very common... - Urban-rural differences in breast cancer incidence in Egypt (1999-2006)Subhojit Dey
Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, MI 48109, USA
Breast 19:417-23. 2010..To describe urban-rural differences in breast cancer incidence in Gharbiah, Egypt and to investigate if these differences could be explained by known risk factors of breast cancer... - Health insurance and discrimination concerns and BRCA1/2 testing in a clinic populationEmily A Peterson
Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
Cancer Epidemiol Biomarkers Prev 11:79-87. 2002..Our research provides evidence that these fears may be discrepant with the actual experiences of patients in high-risk clinics... - From in vitro to in silico and back again: using biological and mathematical synergy to decipher breast cancer cell motilityDevin T Rosenthal
University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
Conf Proc IEEE Eng Med Biol Soc 2010:3261-4. 2010..Fusing biology and mathematics as presented here represents a new direction for biomedical research in which advances in each field synergistically drive discoveries in the other... - Phase II trial of tetrathiomolybdate in patients with advanced kidney cancerBruce G Redman
Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor 48109 0948, USA
Clin Cancer Res 9:1666-72. 2003..Tetrathiomolybdate (TM), a copper-lowering agent, has been shown in preclinical murine tumor models to be antiangiogenic. We evaluated the antitumor activity of TM in patients with advanced kidney cancer in a Phase II trial... - Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a reviewGeorge J Brewer
Department of Human Genetics and Department of Internal Medicine, University of Michigan Medical School, 4009 Buhl Building, Ann Arbor, MI 48109 0618, USA
Integr Cancer Ther 1:327-37. 2002..The authors speculate that the copper level is a primitive angiogenesis and growth-signaling regulator that has been retained throughout evolution... - The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neckTheodoros N Teknos
Department of Otolaryngology Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor, MI 48103, USA
Arch Otolaryngol Head Neck Surg 131:204-11. 2005..To assess the effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth rate in human squamous cell carcinoma (SCC)... - Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling processCatharine Wang
Department of Health Behavior and Health Education, University of Michigan, School of Public Health, Ann Arbor, MI 48104, USA
Am J Med Genet A 134:66-73. 2005..No interaction effects of the two intervention arms were found. The study results support the importance of both strategies as valuable supplements to clinical BRCA1/2 counseling... - Control of copper status for cancer therapyVicki L Goodman
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
Curr Cancer Drug Targets 5:543-9. 2005..Promising results from in vitro experiments, in pre-clinical animal models, and in a phase I clinical trial have led to several phase II trials of TM in patients with advanced cancers... - RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breastCelina G Kleer
Department of Pathology and Internal Medicine, University of Michigan, Ann Arbour, MI 48109 0054, USA
Breast Cancer Res Treat 93:101-10. 2005..We hypothesized that RhoC expression would identify aggressive, non-IBC tumors breast cancer patients at any stage with worse outcomes defined as recurrence and/or metastasis... - CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancerCelina G Kleer
Department of Pathology, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Mich 48109, USA
Cells Tissues Organs 185:95-9. 2007..This review will focus on the current knowledge regarding the function of CCN6 in breast cancer with special emphasis on the emerging role of CCN6 as a regulator of the epithelial phenotype and E-cadherin expression in the breast... - Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hostsCelina G Kleer
Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
Mod Pathol 15:759-64. 2002..This is the first study suggesting a role for EBV in the pathogenesis of fibroadenomas... - Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinomaQuintin Pan
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Mol Cancer Ther 2:617-22. 2003..4 +/- 14.3% greater than that in doxorubicin-treated mice. These results suggest that TM may enhance the rate of pathological complete response when used in combination with an anthracycline in neoadjuvant therapy of breast carcinoma... - Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancerLori J Pierce
Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109 0010, USA
J Clin Oncol 24:2437-43. 2006..We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation carriers with breast cancer versus that of matched sporadic controls... - Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinomaQuintin Pan
Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI 48109, USA
Cancer Res 66:9379-84. 2006..Our study shows, for the first time, that PKC epsilon is involved in a coordinated regulation of RhoA and RhoC activation, possibly through direct post-translational phosphorylation... - Prognostic factors in oral cavity and oropharyngeal squamous cell carcinomaBenjamin Marcus
Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor, Michigan 48103, USA
Cancer 101:2779-87. 2004..0001). CONCLUSIONS: Primary tumor macrophage content is a strong predictor of tumor aggressiveness in HNSCC... - One-hit effects and cancerMaria D Iniesta
Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, 48109, USA
Cancer Prev Res (Phila) 3:12-5. 2010..The work of Bellacosa et al. is an important step toward discerning which pathways may be altered when one BRCA allele is inactivated... - Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine modelClaudell Cox
Department of Otolaryngology-Head and Neck Surgery, University of Michigan Health System, Ann Arbor, 48109, USA
Arch Otolaryngol Head Neck Surg 129:781-5. 2003.... - Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissuesLei Ding
Department of Pathology, University of Michigan Medical School, Ann Arbor 48109, USA
Cancer Res 66:4095-9. 2006..We identify EZH2 as a potential marker for detecting preneoplastic lesions of the breast in vivo and as a possible target for preventative intervention... - Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patientsAn Chi Lo
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
Breast 18:55-9. 2009..Future studies should focus on relating epidemiologic factors to molecular features of IBC in this population... - Inflammatory breast cancer: what are the treatment options?Maria D Iniesta
University of Michigan, Comprehensive Cancer Center, Department of Internal Medicine, Ann Arbor, 48109 0948, USA
Expert Opin Pharmacother 10:2987-97. 2009..Palpable axillary lymphadenopathy is appreciated on the right only. The left breast is uninvolved. The physician is concerned that she may have inflammatory breast cancer... - Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasiaXin Li
Department of Pathology, University of Michigan Medical School, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
Am J Pathol 175:1246-54. 2009.... - Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the worldSubhojit Dey
Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, MI 48109, USA
Med Hypotheses 72:652-6. 2009.... - Genetic determinants of aggressive breast cancerAlejandra C Ventura
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan 48109 0948, USA
Annu Rev Med 59:199-212. 2008..Using IBC as an example, we describe in detail the approaches to identify the genes that are responsible for-and not merely associated with-this disease... - Metastatic dedifferentiated chordoma with elevated beta-hCG: a case reportHidayatullah G Munshi
Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor 48109-0948, USA
Am J Clin Oncol 25:274-6. 2002..However, chemotherapy may play a useful role in the management of systemic disease in patients with dedifferentiated chordoma... - Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North AmericaMaria D Iniesta
Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
Cancer Genet Cytogenet 202:136-40. 2010.... - On the role of cell signaling models in cancer researchAlejandra C Ventura
University of Michigan, Ann Arbor, Michigan 48109, USA
Cancer Res 69:400-2. 2009....
Research Grants
- PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICESofia Merajver; Fiscal Year: 2007..Understand whether TM regulates uPAR expression and erk signaling in her2 and wnt transgenic tumors. ..
- PREVENTION OF MAMMARY CANCER IN HER-2NEU TRANSGENIC MICESofia Merajver; Fiscal Year: 2002..By defining the molecular basis of TM's inhibition of angiogenesis, this work will help tailor the clinical application of TM in cancer. ..